FILE PHOTO: Stefan Oelrich, member of the Board of Management and head of Pharmaceuticals Division of Bayer AG, speaks during an interview on the sidelines of the 38th Annual JP Morgan Healthcare ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

(Reuters) -A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic ...

An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

Bayer UK launches new CanesMeno Educational Hub and product range to transform menopause support: Leverkusen Friday, January ...

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

Bayer AG's stock demonstrated modest trading activity on Friday, settling at €21.80 with a marginal decline of 0.3%. Trading within a narrow corridor, the stock fluctuated between €21.76 and €21.94, ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...